Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00568139 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Side Effects of Mitotane

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2025 to Dec 2027
    • Study completion date: Dec 2027 to Dec 2029
    v14
  2. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Dec 2025 to Dec 2027
    v13
  3. Primary completion date: Jun 2024 to Dec 2024
    • Study completion date: Dec 2024 to Dec 2025
    v12
  4. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 2023 to Jun 2024
    • Site details revised
    v11
  5. Enrollment target: 200 to 400
    • Study completion date: Dec 2023 to Dec 2024
    • Eligibility criteria expanded, about 6 words
    • Study arms: 2 to 1
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Primary completion date: Dec 2021 to Dec 2023
    • Study completion date: Dec 2022 to Dec 2023
    v8
  3. Primary completion date: Dec 2020 to Dec 2021
    • Primary endpoint revised
    v7
  4. Primary completion date: Dec 2018 to Dec 2020
    • Study completion date: Dec 2019 to Dec 2022
    v6
  5. Re-verified, no change to tracked fieldsv5
  6. Primary completion date: Dec 2018
    • Study completion date: Dec 2013 to Dec 2019
    v4
  7. Re-verified, no change to tracked fieldsv3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study completion date: Dec 2010 to Dec 2013
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane
Trial Details
NCT Number NCT00568139
Lead Sponsor University of Wuerzburg
Conditions
(from sponsor)		 Adrenocortical Carcinoma
Related terms Adrenal Gland Neoplasms, Adrenocortical Carcinoma
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov